Gerresheimer's Liquidity Lifeline: Asset Sale Follows Index Expulsion

German pharma packaging group Gerresheimer scrambles for cash, selling Centor Inc. after an accounting scandal froze capital markets and triggered a technical loan default.

The forced sale of a major US subsidiary has become the most urgent priority for German pharmaceutical packaging group Gerresheimer AG. With its stock ejected from the SDAX index and its access to capital markets frozen by an accounting scandal, management is scrambling to secure liquidity. The planned divestment of Centor Inc., a US plastics specialist carried on the books at 292 million euros, is a radical step to generate cash.

This drastic move follows the company's official removal from the SDAX, a consequence of its failure to publish an audited annual report. The delisting compounds selling pressure, as index-tracking funds are now forced to mechanically dump the stock. The share price, currently at 17.17 euros, reflects the crisis, having plummeted 68.47% over the past twelve months and 38% since the start of the year.

At the heart of the turmoil are severe accounting irregularities under investigation by German financial watchdog BaFin. The probe has expanded to scrutinize leasing liabilities worth 65.5 million euros and capitalized development costs of 29.4 million euros. A core focus is the alleged improper booking of revenue through "bill-and-hold" agreements, where sales were recorded before goods were shipped to customers.

The company's auditor, KPMG, is also in the regulatory crosshairs. The auditor oversight body APAS has launched a procedure against the firm for issuing an unqualified audit opinion on the flawed 2024 financial statements. This lack of a certified audit has triggered a complete blackout of financial reporting. The publication of Q1 2026 results and the annual shareholder meeting have been postponed indefinitely.

This reporting halt has pushed Gerresheimer into a technical default on its loans for breaching disclosure covenants. To navigate this period, interim CEO Uwe Röhrhoff is not only selling Centor but is also closing the container glass plant in Chicago Heights by the end of 2026, shifting capacity to Italy and India. Further straining the balance sheet are expected non-cash impairment charges that could reach 240 million euros.

All forward guidance now carries a significant caveat. The management's revenue forecast of 2.3 to 2.4 billion euros for the current year is explicitly conditional on successful negotiations with banks for covenant waivers and a viable outcome from the BaFin investigations. The next critical date is June 2026, when the long-delayed, audited financial statements for 2025 are finally due.

Until those validated numbers are presented, investors are left with no reliable financial data. The company's survival strategy hinges on the asset sale and ongoing lender talks, while the market awaits clarity on the full extent of the accounting errors and the future earning power of a restructured Gerresheimer.